MAPT and supranuclear palsy, progressive, 1: [3H]OXD-2314 was compared to tritium-labeled PI-2620, florzolotau, and OXD-2115 in affinity and competitive binding assays against AD, CBD, PSP, and PiD tissues and was shown to be twice as potent to tau aggregates in PSP tissue, 10-times more potent in CBD tissue, and equipotent in AD tissues.